Biotech Values

[jbog]

Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report
Sep. 30, 2024 11:25 AM ET3 Comments

Roche (OTCQX:RHHBY) said Monday that three obesity and diabetes drug candidates acquired through its takeover of Carmot Therapeutics have the potential to generate over $3.6B in combined annual sales, according to a report.

The three candidates were identified as CT-388, CT-996 and CT-868. Roche said it sees the combined potential sales of the products at more than CHF 3B, or around $3.6B. It added that it sees at least seven of its drugs in development having potential peak sales of more than CHF 3B, according to Reuters.

Roche made the comments in connection with its 2024 Pharma Day. A presentation of its R&D activities was posted on its website early Monday.

The Swiss drugmaker acquired Carmot for $2.7B in January.

https://seekingalpha.com/news/4154563-roche-sees-carmot-obesity-drugs-potential-peak-sales-at-4b-report